Methotrexate: Nursing Drug Guide, Weekly-Dose Errors & Myelosuppression
One weekly tablet can control rheumatoid arthritis or psoriasis—but giving that same dose every day has caused fatal bone marrow and organ toxicity. Verify once-weekly scheduling, trend CBC and liver tests, coordinate folic acid per order, and know when leucovorin rescue is needed.
FDA labeling reports deaths when patients took once-weekly methotrexate every day. Serious reactions—including myelosuppression, mucositis, hepatotoxicity, pulmonary toxicity, and renal injury—require close monitoring and prompt hold/discontinue decisions. Methotrexate is contraindicated in pregnancy for non-neoplastic disease and in severe hypersensitivity including anaphylaxis.
📋 Contents
⚡ Quick facts
💡 Key takeaway
Before every dose: confirm once weekly (not daily), review latest CBC and symptoms (mouth sores, fever, bleeding), verify pregnancy status in patients who can become pregnant, and hold with prescriber/pharmacist contact for cytopenias, severe stomatitis, or suspected overdose.
Most common brand names
Methotrexate is available as generic tablets and multiple branded formulations. Nurses must match total weekly milligrams, route, and schedule—not just the drug name.
Common names include Trexall (oral), Otrexup and Rasuvo (subcutaneous), RediTrex (injection), and Xatmep (oral solution). Oncology and rheumatology regimens differ—never assume a neighbor’s dose or schedule applies to your patient.
Why we give it — Indications
Per FDA methotrexate tablet labeling, methotrexate is a dihydrofolate reductase inhibitor used across oncology and immune-mediated disease. Nursing priorities shift with indication, but schedule verification and toxicity monitoring apply to all regimens.
| Use | Detail |
|---|---|
| Rheumatoid arthritis (adults) | Starting dose 7.5 mg orally once weekly with escalation to optimal response; doses >20 mg once weekly increase serious adverse reaction risk. Folic acid or folinic acid supplementation is recommended to reduce adverse reactions. |
| Severe psoriasis (adults) | 10–25 mg orally once weekly until adequate response; do not exceed 30 mg per week. Folic/folinic acid supplementation recommended. Monitor liver tests and cumulative dose-related hepatotoxicity risk. |
On a small screen, swipe or scroll sideways to see the full table.
How it works
Methotrexate inhibits dihydrofolate reductase, blocking conversion of dihydrofolates to tetrahydrofolates needed for purine and thymidylate synthesis. Rapidly dividing tissues—bone marrow, GI mucosa, fetal cells—are especially sensitive. In rheumatoid arthritis and psoriasis the full mechanism is not specified in the reviewed prescribing information beyond antifolate effects on immune and skin cell proliferation.
Dosing overview
Dosing is indication-specific and often once weekly for RA, psoriasis, and many pJIA regimens, but oncology metronomic regimens may use different weekly patterns. Always read the exact order—medication errors have led to deaths.
Missed dose: Not specified in the reviewed prescribing information. Contact the prescriber or pharmacist before giving a missed weekly dose—do not double the weekly dose without explicit orders.
Before you give it — Safety check
Pretreatment checks
- Confirm pregnancy status in females of reproductive potential before starting or continuing non-neoplastic therapy—methotrexate is contraindicated in pregnancy for these indications
- Verify once-weekly schedule on MAR and patient teach-back; reconcile home supply and pillbox layout during medication reconciliation
- Review baseline and recent CBC, liver tests, renal function, infection symptoms, alcohol use, and interacting drugs (NSAIDs, antibiotics, folic acid timing)
Contraindications
- Pregnancy when used for non-neoplastic diseases (e.g., RA, psoriasis)
- History of severe hypersensitivity to methotrexate, including anaphylaxis
- Not specified in the reviewed prescribing information as absolute contraindications beyond the above—use caution with significant renal impairment, hepatic disease, immunosuppression, and third-space fluid collections per warnings
Important interactions
| Drug / class | Effect | Nursing action |
|---|---|---|
| NSAIDs (e.g., ibuprofen) and salicylates | May increase methotrexate plasma concentrations and severe adverse reactions including myelosuppression and GI toxicity | Screen MAR and home meds; monitor CBC and renal function; hold methotrexate and notify prescriber/pharmacist if toxicity suspected |
| Probenecid / nephrotoxic or hepatotoxic drugs / oral antibiotics | Reduced clearance or additive organ toxicity increases methotrexate exposure | Closely monitor methotrexate adverse reactions when coadministration cannot be avoided; verify antibiotic choice with pharmacy |
| Folic acid / folinic acid | Supplementation reduces RA/psoriasis/pJIA adverse reactions but may decrease antitumor effectiveness in neoplastic disease | Give folic/folinic acid only as directed; separate timing per prescriber; do not substitute folic acid for leucovorin rescue after overdose |
On a small screen, swipe or scroll sideways to see the full table.
Administration
Route: Oral tablet (often 2.5 mg tablets combined to total weekly dose), subcutaneous injection, intramuscular, or intravenous per order. When switching routes, alternative dosing may be required per labeling.
- For once-weekly regimens, administer the full weekly dose on the prescribed day—not divided across seven days unless explicitly ordered (oncology protocols differ)
- Take folic or folinic acid supplementation per prescriber schedule (commonly on non-methotrexate days for RA/psoriasis)
- Handle tablets as cytotoxic drug per institutional policy; use gloves if manipulating tablets for patients when required by facility hazardous drug procedures
Labeling states that mistakenly taking the recommended weekly dosage daily has led to fatal adverse reactions. Use explicit day-of-week labeling, teach-back, and pharmacy verification at care transitions.
Expected therapeutic response
- Rheumatoid arthritis: improved joint pain/swelling—many responses occur between 3 and 12 weeks per labeling
- Psoriasis: reduced plaque severity and area over weeks to months with weekly therapy
- Tolerable mild nausea or fatigue may occur early; worsening mouth sores, infection, or cytopenias are not therapeutic responses—hold and reassess
Red flags — Stop and act
Methotrexate toxicity can progress quickly after dosing errors or drug interactions. Escalate early rather than treating symptoms alone.
- Fever, rigors, or signs of infection in a patient with falling WBC or platelets—consider sepsis until proven otherwise
- Severe stomatitis, oral ulcers, intractable nausea/vomiting, hematemesis, melena, or severe abdominal pain
- New or worsening cough, dyspnea, or hypoxia—possible methotrexate pneumonitis
- Jaundice, dark urine, RUQ pain, or rapidly rising transaminases
- Suspected daily dosing of weekly methotrexate, overdose, or pregnancy during non-neoplastic therapy—hold and activate prescriber/pharmacy/toxicology pathways
Adverse effects
| Adverse effect | Frequency / severity | Nursing response |
|---|---|---|
| Ulcerative stomatitis / mucositis | Common; up to ~10% in non-neoplastic use per label | Assess oral mucosa each visit; hold and notify prescriber for severe stomatitis; reinforce folic acid timing per order |
| Myelosuppression (leukopenia, thrombocytopenia, anemia, pancytopenia) | Boxed warning; can be severe and life-threatening | Review CBC trends before dosing; hold for critical counts per protocol; monitor for fever, bleeding, infection |
| Nausea, vomiting, abdominal distress | Common per label | Document GI symptoms; hold for severe GI toxicity, hematemesis, melena, or persistent vomiting per labeling |
| Hepatotoxicity (fibrosis, cirrhosis, liver failure) | Boxed warning; risk increases with alcohol and cumulative dose | Trend liver function tests; assess for jaundice; hold and escalate for rising transaminases or clinical liver injury |
| Pulmonary toxicity (interstitial pneumonitis) | Can be irreversible or fatal per label | Monitor cough, dyspnea, fever; hold and notify prescriber for new pulmonary symptoms |
| Severe dermatologic reactions (TEN, SJS, erythema multiforme) | Postmarketing; can be fatal | Hold for new or worsening rash; teach sun protection; escalate widespread blistering immediately |
On a small screen, swipe or scroll sideways to see the full table.
Overdose, toxicity, and antidote
Fatal overdosage has occurred with methotrexate, most often when a once-weekly regimen was taken daily by mistake per FDA labeling.
Manifestations
Overdose may present with hematologic and GI toxicity: leukopenia, thrombocytopenia, anemia, pancytopenia, mucositis, stomatitis, nausea, vomiting, GI ulceration or bleeding. Sepsis, septic shock, renal failure, and aplastic anemia have also been reported; some patients had no early symptoms.
Antidote and management
- Leucovorin (folinic acid) or levoleucovorin is indicated to diminish methotrexate adverse reactions after overdosage—administer as soon as possible per leucovorin prescribing information
- Monitor serum methotrexate concentrations and creatinine to guide leucovorin therapy
- Glucarpidase is indicated for toxic plasma methotrexate concentrations (>1 µmol/L) with delayed clearance due to impaired renal function—refer to glucarpidase labeling
- Supportive care includes hydration and urinary alkalinization per toxicology protocol
- Contact local poison control or medical toxicology services per facility protocol and local emergency guidance for suspected overdose
Do not wait for full symptom development after a confirmed daily-dosing error or large unintended exposure—activate prescriber, pharmacy, and toxicology pathways immediately while obtaining CBC and methotrexate level per protocol.
Look-alike / sound-alike and error prevention
- Weekly vs daily schedule—most fatal methotrexate errors involve giving a weekly dose every day; verify “once weekly” on the MAR and teach-back before every new start or transfer
- Methotrexate vs metformin, metoclopramide, metolazone—confirm drug name, indication (DMARD/oncology), and schedule during medication reconciliation
- 2.5 mg tablet multiplication—15 mg may require six tablets; independent double-check tablet count and total milligrams
- Oral vs subcutaneous/injection—route and frequency differ when switching formulations; pharmacy must clarify equivalent weekly dose
- Folic acid vs methotrexate—similar pill appearance in home pillboxes; separate storage and explicit day-of-week labeling reduce swaps
- Intrathecal vs systemic—not specified in the oral tablet labeling reviewed here; when intrathecal methotrexate is used in oncology, follow institutional high-risk chemotherapy verification separate from outpatient RA dosing
Practical bedside notes
| Topic | Bedside guidance |
|---|---|
| Administration timing | Once-weekly regimens are a single weekly dose—not divided daily; label the chosen day (e.g., “Methotrexate Saturday”) |
| Food | Food delays absorption and lowers peak concentration per label—take consistently with or without food as ordered |
| Folic acid | Take folic/folinic acid only as directed; do not self-start in oncology patients where it may reduce antitumor effect |
| Alcohol | Heavy alcohol increases hepatotoxicity risk—review intake at each visit |
| Handling | Tablets are cytotoxic—avoid crushing unless pharmacy approves manipulation; follow hazardous drug handling if institutional policy applies |
| Missed weekly dose | Not specified in the reviewed prescribing information—contact prescriber or pharmacist; do not double the weekly dose without orders |
| Ask pharmacy when | Switching oral to SC/IM/IV, falling counts, suspected overdose, NSAID or antibiotic added, or pregnancy status changes |
On a small screen, swipe or scroll sideways to see the full table.
High-risk populations
| Population | Considerations |
|---|---|
| Renal impairment (CLcr <90 mL/min) | Reduced elimination increases adverse reaction risk—closely monitor and reduce dose or discontinue as appropriate per label |
| Hepatic disease, alcohol use, or cumulative dose >1.5 g (psoriasis) | Increased hepatotoxicity including fibrosis/cirrhosis—monitor LFTs; fibrosis may occur without symptoms in psoriasis per label |
| Older adults, dehydration, ascites/pleural effusion (third-space) | Higher toxicity risk with third-space accumulation per warnings—monitor closely and adjust per prescriber |
| Pregnancy | Contraindicated for non-neoplastic disease. Can cause embryo-fetal toxicity including fetal death. Females of reproductive potential need pregnancy testing before start, effective contraception during therapy and 6 months after final dose; males with female partners of reproductive potential need contraception during therapy and 3 months after final dose per label. |
| Lactation | Present in human milk in low amounts per label. Instruct women not to breastfeed during treatment and for 1 week after the final dose because of potential serious adverse reactions in the breastfed child. |
On a small screen, swipe or scroll sideways to see the full table.
Monitoring and documentation
Monitor
- Complete blood count (CBC) at baseline, periodically during treatment, and when clinically indicated—watch for leukopenia, anemia, thrombocytopenia, pancytopenia
- Liver tests at baseline and periodically; renal function (creatinine/CrCl); assess oral mucosa, lungs, skin, and infection symptoms each visit
- For high-dose oncology regimens: methotrexate levels and leucovorin rescue per protocol—not specified for routine low-dose RA monitoring in oral tablet labeling
Document
- Weekly dose (mg), route, day of week, tablet count verification, and patient/caregiver teach-back on schedule
- CBC and LFT results reviewed before administration; hold actions and prescriber/pharmacist notifications
- Folic acid plan, contraception counseling for reproductive potential, infection screening, and overdose/toxicology activation if dosing error suspected
Patient teaching
- Take methotrexate only on your prescribed weekday—this is usually once per week, not every day; daily dosing has caused deaths
- Report fever, sore throat, mouth sores, unusual bleeding or bruising, shortness of breath, severe nausea, or yellowing skin immediately
- Take folic acid only as directed and avoid starting extra folic acid or NSAIDs without checking with your care team
- Use effective contraception as prescribed; tell your team immediately if pregnancy is possible or confirmed
- Avoid live vaccines during therapy per labeling; limit alcohol; use sun protection because methotrexate increases photosensitivity
The Hold Rule
Do not give and contact the prescriber/pharmacist when:
- Suspected or confirmed daily dosing of a weekly methotrexate regimen, or any unintended overdose—hold and activate prescriber/pharmacy/toxicology immediately
- Significant myelosuppression, severe stomatitis/mucositis, or active serious infection per prescriber parameters
- Pregnancy in non-neoplastic therapy, anaphylaxis/hypersensitivity, or severe pulmonary/hepatic/renal/GI toxicity
- Critical lab values or symptoms per institutional protocol (e.g., neutropenia, thrombocytopenia, rising transaminases) pending prescriber review
- Unclear order (wrong frequency, wrong total mg, duplicate DMARD such as overlapping methotrexate plus another antimetabolite without clarification)
Hold parameters may vary by institutional protocol. Follow prescriber orders, pharmacy guidance, and facility policy.
Clinical practice integration and workflow
Methotrexate is a cornerstone DMARD and oncology agent, but its narrow therapeutic window and fatal error history demand the same rigor as high-alert chemotherapy in outpatient clinics and med-surg units. Build weekly schedule verification into every administration and transfer of care.
1. Check-before-you-give protocol
- Right patient, drug, weekly dose (total mg), route, and day of week—never assume “MTX 15 mg” means daily
- Review latest CBC, LFTs, creatinine, infection symptoms, mouth exam, and pregnancy status when applicable
- Reconcile NSAIDs, antibiotics, folic acid, and other DMARDs/biologics on the MAR before each weekly dose
- Confirm patient/caregiver verbalizes the correct weekday and that home pillboxes separate methotrexate from daily vitamins or folic acid
2. High-alert and safety badge
High-alert medication — weekly dosing; daily administration errors have caused deathsFDA labeling and ISMP emphasize methotrexate as a high-risk drug for wrong-frequency errors. Treat oral weekly methotrexate with independent double-checks, explicit day-of-week documentation, and teach-back at every new start, dose change, or transfer.
3. Clinical workflow: hold and question rules
- If a patient reports “I take my rheumatology pills every morning,” pause and clarify which drug is weekly before administering methotrexate
- If CBC drops or mouth sores develop, hold the next weekly dose until prescriber/pharmacist review—do not skip monitoring and give the next week on schedule without clearance
- For suspected overdose, hold all methotrexate, obtain CBC and methotrexate level per protocol, and initiate leucovorin only per prescriber/toxicology—not routine folic acid
4. Critical teach-back questions
- “On which day do you take methotrexate, and how many days each week?” (Patient should name one weekday and state once weekly—not daily.)
- “What symptoms mean you should call before your next dose?” (Patient should include fever, mouth sores, bleeding/bruising, shortness of breath, severe nausea, or yellow skin/eyes.)
5. Care coordination
Pharmacist: Clarify weekly mg and tablet count, folic acid timing, interaction review (NSAIDs, antibiotics), leucovorin/glucarpidase orders after overdose, and route switches between oral and injectable formulations
Prescriber / rheumatology or oncology: Notify for cytopenias, mucositis, pulmonary symptoms, LFT elevation, pregnancy, or dosing errors; coordinate hold, dose reduction, or rescue therapy
🧠 Quick mental checklist
- Is this order once weekly—not daily—and is today the correct weekday?
- What do the latest CBC and LFTs show, and any fever, mouth sores, or bleeding?
- Are NSAIDs, new antibiotics, or duplicate folic acid/methotrexate swaps in play?
- Is pregnancy possible, and is contraception counseling documented for reproductive potential?
- If an overdose or daily-dosing error occurred, has leucovorin/toxicology been activated—not just routine folic acid?
Methotrexate NCLEX practice questions
Practice NCLEX-style clinical judgment practice for methotrexate with a tabbed outpatient case (MAR, labs, history, nursing notes), then priority action, cue recognition, CBC/LFT trend interpretation, matrix urgency sorting, leucovorin judgment, and weekly-schedule cloze—recognise cues → analyse → prioritise → act → evaluate outcomes around weekly-dose errors and myelosuppression.
Select a tab to view MAR, labs, History, and nursing note details for this case.
- Methotrexate 15 mg PO weekly — due today (patient usually takes Saturdays)
- Folic acid 1 mg PO daily except methotrexate day per order
- Ibuprofen 400 mg PO TID PRN joint pain
- Prednisone 5 mg PO daily
- Chart review: patient took methotrexate Monday, Tuesday, and Wednesday this week believing it was a daily vitamin
- CBC: WBC 6.2 → 4.1 → 2.8 ×10³/µL; Hgb 12.4 g/dL stable; platelets 210 → 158 → 92 ×10³/µL
- LFTs: AST 28 → 34 → 48 U/L; ALT 22 → 31 → 44 U/L
- Serum creatinine 0.9 mg/dL stable
- Methotrexate level: pending per toxicology protocol after dosing error reported
- 52-year-old with rheumatoid arthritis on methotrexate 8 weeks
- Not pregnant; uses contraception; last pregnancy test negative 6 weeks ago
- Social history: 2 alcoholic drinks nightly
- Home pillbox mixes methotrexate and folic acid tablets without weekday labels
- 0900: Oral ulcers on buccal mucosa; reports burning with eating
- 0915: Temperature 38.1 °C; denies cough
- 0920: Patient states, “I thought methotrexate was like my folic acid—every morning.”
- 0930: Nurse holding today’s scheduled weekly dose pending prescriber/pharmacist review
Answer key & rationale
Frequently asked questions
Can methotrexate for rheumatoid arthritis be taken every day?
No for standard weekly RA regimens. FDA labeling specifies once-weekly dosing (starting 7.5 mg orally once weekly with escalation) and warns that taking the recommended weekly dosage daily has led to fatal adverse reactions. Always follow the exact order and teach once-weekly scheduling.
Why is folic acid given with methotrexate, and can it replace leucovorin after an overdose?
Folic or folinic acid supplementation reduces adverse reactions in RA, pJIA, and psoriasis per labeling but may decrease antitumor effectiveness in neoplastic disease. It is not interchangeable with leucovorin rescue—leucovorin/levoleucovorin is indicated after methotrexate overdosage per FDA overdosage section.
What should I check before giving methotrexate?
Confirm once-weekly schedule and total milligrams, review CBC and liver/renal tests, assess for mouth sores, fever, infection, or bleeding, verify pregnancy status in reproductive potential, reconcile NSAIDs and antibiotics, and confirm folic acid timing per prescriber.
When should a nurse hold methotrexate?
Hold for suspected daily dosing of a weekly regimen or overdose, significant cytopenias or severe stomatitis, pregnancy in non-neoplastic therapy, anaphylaxis, serious infection, or severe pulmonary/hepatic/renal/GI toxicity pending prescriber/pharmacist review per labeling and institutional parameters.
Can patients breastfeed while taking methotrexate?
No. FDA labeling instructs women not to breastfeed during methotrexate treatment and for 1 week after the final dose because of potential serious adverse reactions in the breastfed child. Methotrexate is present in human milk in low amounts.
References
-
U.S. FDA DailyMed — Methotrexate tablets prescribing information (Teva Pharmaceuticals; revised September 2025)https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9b34b1d8-d125-41a2-9f6f-3fab67b573bd
-
U.S. FDA DailyMed — Methotrexate injection prescribing information (Pfizer)https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dd035a9f-cd40-4314-b9d8-2294b8a924e2
-
NIH StatPearls — Methotrexate (NCBI Bookshelf)https://www.ncbi.nlm.nih.gov/books/NBK501194/
-
U.S. FDA — Methotrexate drug safety information for healthcare professionalshttps://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/methotrexate-information
-
Institute for Safe Medication Practices (ISMP) — High-alert medication: methotrexatehttps://www.ismp.org/node/472
Review and transparency
This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.
Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.